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Natural products (NPs) continue to play a pivotal role in drug discovery programs. The rapid develop-
ment of synthetic biology has conferred the strategies of NPs production. Synthetic biology is a new
engineering discipline that aims to produce desirable products by rationally programming the biological
parts and manipulating the pathways. However, there is still a challenge for integrating a heterologous
pathway in chassis cells for overproduction purpose due to the limited characterized parts, modules
incompatibility, and cell tolerance towards product. Enormous endeavors have been taken for mentioned
issues. Herein, in this review, the progresses in naturally discovering novel biological parts and rational
design of synthetic biological parts are reviewed, combining with the advanced assembly technologies,
pathway engineering, and pathway optimization in global network guidance. The future perspectives are
also presented.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Natural products, produced by bacteria, fungi, and plants, play a
highly signiﬁcant role in the drug discovery and developmenti Communications Co. This is an open access article under the CC BY-NC-ND license
J. Li et al. / Synthetic and Systems Biotechnology 1 (2016) 221e229222process [1].Many of them, such as paclitaxel [2],digitalis [3],codeine
[4],and erythromycin [5]are highly concerned with astonishing
biological activities and are used for diverse purposes such as
anticancer, congestive heart failure treatment, alleviating pains,
and antibacterial, respectively. Unfortunately, these desired prod-
ucts are commonly isolated from native organism in low yield or
synthesized with inefﬁcient or unfeasible because of their complex
structures [2,5].
Synthetic biology provides an alternative approach to produce
these valuable products for industry application [6,7].It aims to
reduce the complex biosynthetic systems in originated organism to
a simpliﬁed, reliable, quality-controlled heterologously artiﬁcial
biological network to achieve our special goals. The biological parts,
devices, or modules related to the targeting biosynthetic pathway
are assembled and transplanted from the natural host into a
genetically tractable host system such as Escherichia coli, Saccha-
romyces cerevisiae.
The classical engineering strategies have been widely provided
for our purposes in this approach. For example, overexpress en-
zymes responsible for putative bottleneck steps in biosynthetic
pathway [8], delete competing steps [9], transfer biosynthetic
machinery to an amenable heterologous host [10],re-regulate reg-
ulatory circuits to awaken unknown natural compounds [11],or
even create enzyme variations by domain shufﬂing [12].Never-
theless, there is still a challenge when integrating a heterologous
pathway for complex natural products in chassis cells for over-
production purpose due to the limited characterized parts, modules
incompatibility, and cell tolerance towards product. Thus in this
review, we will discuss the strategies to deal with the problems
mentioned above for products production.2. Synthetic biological parts: screening, characterization and
rational design
Biological parts (BioParts), including promoters, terminators,
ribosome binding sites (RBS), and protein coding sequences (CDSs),Fig. 1. Synbiological systems for complex natural products betc. are the basic building blocks widely used in synthetic biology
(Fig. 1). [13]The characterized biological parts can be designed and
grouped into a biological device at large-scale to obtain speciﬁc
biological functions in an engineered cell. With the development of
genome/transcriptome sequencing and bioinformatics, huge
numbers of novel biological parts can be precisely predicted
[14e29],and many of them were functionally characterized and
standardized to build up open access libraries by academy appli-
cation, e.g., the Registry of Standard Biological Parts established by
Massachusetts Institute of Technology (http://partsregistry.org)
and the Joint BioEnergy Institute Inventory of Composable Ele-
ments (JBEI-ICEs, http://www.jbei.org) set up by Jay D. Keasling's
group(Table 1). [30e35] However, only very limited biological parts
have been explored to date. Take microorganism for example, only
1% of total resource can be cultured by current technology. Tradi-
tional culture methods result in an extremely low efﬁciency in
exploration of natural biological element. As to plant, the problem
becomes more prominent: much larger genome but trace has been
sequenced, enormous novel parts are still cryptic and eager to be
discovered and characterized. In terms of announced biological
parts, it is quite necessary to performmanual construction based on
the existing knowledge andmake full use of the library resources of
natural elements.2.1. Discovery of novel BioParts
In most case, Bioparts can be obtained directly from native or-
ganism. And among all of the BioParts, genes encoding the
biosynthetic enzymes play a prominent role. Serious efforts are
under way for the discovery of novel catalytic parts continuously,
though it is not a trivial work. Recent advances in genome
sequencing and bioinformatics have shown that in bacteria and
fungi, the genes responsible for the assembly of a metabolite are
generally clustered together within the chromosome [3,36e38].
But the metabolites derived from plant are formed in much
more complex condition, the genes exist in a cassette withiosynthesis: from BioParts to modules, then to systems.
Table 1
Tools and databases for screening of biological parts.
Tools/databases Websites Description References
TransTermHP http://transterm.cbcb.umd.edu/ Predicted rho-independent transcription
terminators in bacterial genomes.
Kingsfold et al. [14]; Ermolaeva et al.
[15]
rVISTA 2.0 http://rvista.dcode.org/ Evolutionary analysis of transcription factor
binding sites.
Loots et al. [16]
PRISM http://genie.dartmouth.edu/prism/ Bounded search for de novo identiﬁcation of
degenerate cis-regulatory elements.
Carlson et al. [17]
SCOPE http://genie.dartmouth.edu/scope A powerful motif ﬁnder designed to be of
particular for cis-regulatory element prediction.
Chakravarty et al. [18] Carlson et al.
[19]
Promoter 2.0 http://www.cbs.dtu.dk/services/promoter/ Prediction of eukaryotic Pol II promoters. Knudsen [20]
Standard Virtual
Biological Parts
http://models.cellml.org Mathematical model components describing
the function of SBPs which can be downloaded,
extended and recombined to aid the design, in
silico, of synthetic biological systems.
Cooling et al. [21]
BEAM Identiﬁcation for cis-regulatory elements. Carlson et al. [22]
PromH http://www.softberry.com/berry.phtml?topic¼promh Promoter prediction Solovyev et al. [23]
RibEx http://www.ibt.unam.mx/biocomputo/ribex.html A tool for searching riboswitches and other
conserved bacterial regulatory elements.
Abreu-Goodger et al. [24]
tRNAscan-SE http://lowelab.ucsc.edu/tRNAscan-SE/ Detection of tRNAs Schattner et al. [25]
snoscan http://lowelab.ucsc.edu/snoscan/ Delection of methylation-guide snoRNAs Schattner et al. [25]
snoGPS http://lowelab.ucsc.edu/snoGPS/ Delection of pseudouridylationguide snoRNAs Schattner et al. [25]
DBD http://transcriptionfactor.org A database of predicted sequence-speciﬁc DNA-
binding transcription factors (TFs) for over 700
available proteomes.
Wilson et al. [26]
Rfam/Rfam 12.0 http://rfam.sanger.ac.uk/ http://rfam.janelia.org/
http://rfam.xfam.org
A RNA families database (tRNA, rRNA, snoRNAs
and miRNAs)
Gardner et al. [27] Nawrocki et al. [28]
SMART 6 http://smart.embl.de/ An online tool for the identiﬁcation and
annotation of protein domains.
Letunic et al. [29]
SCPD http://cgsigma.cshl.org/jian The promoter database of Saccharomyces
cerevisiae
Zhu et al. [30]
TFD A specialized transcription factors database Ghosh [31]
Knowledgebase of
Standard Biological
Parts (SBPkb)
http://sbolstandard.org/ A database allows researchers to query and
retrieve standard biological parts for research
and use in synthetic biology.
Galdzicki et al. [32]
Pfam http://pfam.sanger.ac.uk/
http://pfam.janelia.org/ http://pfam.sbc.su.se/
A widely used database of protein families and
domains.
Finn et al. [33]
WebGeSTer DB http://pallab.serc.iisc.ernet.in/gester A database comprises of a million terminators
identiﬁed in 1060 bacterial genome sequences
and 798 plasmids.
Mitra et al. [34]
Registry of Standard
Biological Parts
http://partsregistry.org/ A growing collection of genetic parts that can be
mixed and matched to build synthetic biology
devices and systems.
Massachusetts Institute of Technology
JBEI-ICEs http://www.jbei.org/ An open source registry platform for biological
parts registry.
Ham et al. [35]
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cultured in genome. Generally, transcriptome data provided useful
information for the desired gene mining. The plants UGTs contain a
highly conserved consensus signature sequence called the PSPG
motif. With the aims to elaborate the biosynthetic pathway of
ginsenosides and assembly the pathway in yeast, Yan et al. [39]
established a proprietary cDNA database including 479,689 cDNA
contigs based on 9 Panax EST datasets available from the NCBI
GenBank. 512 contigs were identiﬁed potentially encoding plant
UGTs, and 158 contigs including the ORFs were clustered into 80
operational taxonomic units based on protein sequences at 95%
similarity cutoff. Finally, 5 UGTPgs showed obvious glycosylation
activity on protopanaxadiol (PPD), protopanaxatriol (PPT) and their
ginsenosides, which were further used in the metabolic engineer-
ing of ginsensides in yeast.
Except for the native organism, coding genes can also be isolated
from other optional resources. Structural similar compounds exist
in separated organisms and the equivalent genes may be discov-
ered by bioinformatic tools. These genes are interchangeable units
and were chosen, then assembled in a designed pathway to pro-
duce goals. Thus, the simplest idea behind the metabolic engi-
neering has been to simply redirect the metabolites by alter genetic
coding sequences. The isoprene synthase (IspS), which catalyzes
the formation of isoprene from dimethylallyl pyrophosphate(DMAPP), is present in various plants including moss, gymno-
sperms, and angiosperms. Codon-optimized or native ispS genes
from Eucalyptus globulus, Populus alba, P. trichocarpa, P. deltoids,
P. canescens, and Pueraria montana without the chloroplast transit
sequence were expressed under the control of various promoters in
Synechococcus elongatus [40].The amount of isoprene produced by
these IspS-expressing S. elongatus strains varied considerably. The
strain expressing codon-optimized E. globulus IspS produced
roughly 30-fold higher amount of isoprene than the strain
expressing P. montana IspS. The western blot analysis and mea-
surements of the isoprene synthase activities in crude cell lysates
demonstrated great variations of the various IspS in catalytic ac-
tivity and protein abundance in the cyanobacterial host.
Fungal endophyte is the other optional resources for genes
exploring. It resides in the internal tissues of living plants occur in
almost every plant on earth from the arctic to the tropics. The
endophyteehost relationship is described as a balanced symbiotic
continuum ranging from mutualism through commensalism to
parasitism. Three molecular probes based on key genes of taxol
biosynthesis, ts (encoding taxadiene synthase), dbat (encoding 10-
deacetylbaccatin III-10-O-acetyltransferase), and bapt (encoding C-
13 phenylpropanoyl side chain-CoA acyltransferase), were applied
to screen taxol-producing endophytic fungus [41].Three fungus
Guignardia mangiferae HAA11, Fusarium proliferatum HBA29, and
J. Li et al. / Synthetic and Systems Biotechnology 1 (2016) 221e229224Colletotrichum gloeosporioides TA67 were capable of producing
taxol which were validated by HPLC-MS. Thanks to the relatively
small genomes and metabolically genetic cluster, these microor-
ganisms provided a fascinating reservoir for the diversity of taxol
biosynthetic genes, thus could signiﬁcantly expand the number of
known taxol biosynthetic genes to elucidate the whole pathway
and provide the basis for heterologous production.
2.2. Rational design of BioParts
Generally, there are two available main approaches for manual
construction of library according to the design principle: the ﬁrst
one is based on randommutagenesis and library screening, and the
other one is artiﬁcial design based on quantitative prediction
models [42].Random mutagenesis can be easily introduced via er-
ror prone PCR by slightly adjusting the reaction conditions (e.g.
different concentration of magnesium and manganese ions, un-
balanced the concentration of dNTPs, or DNA polymerase with low
ﬁdelity). However, it is still a laborious work with low efﬁciency to
acquire a controllable and quantitative biological part from
different kinds of libraries for complex biological systems design.
So, it is a strong demand for regulatory element from random
screening to quantitative design in an engineered system. Regula-
tory elements with desired strengths/activities, e.g., promoters/
RBSs for transcriptional/translational controls, are indispensable
tools to accurately regulate the gene expression for rational
pathway engineering.
More recently, great advances in synthetic biology have brought
back the sequence-activity modeling to the forefront. For instance,
Rhodius et al. [43]scored various motifs of E. coli sE binding pro-
moters and correlated promoters scores based on position weight
matrix (PMW)models. Salis et al. [44]targeted translation initiation
process and developed an equilibrium statistical thermodynamics
model for designing synthetic RBSs. De Mey et al. [45]established a
correlation between the entire sequence and strength by applying
partial least squares (PLS) regression method. However, building
precise models that can predict the activity of regulatory elements
and quantitatively design elements with desired strength is still a
challenge.
As a powerful machine learning algorithm, artiﬁcial neural
network (ANN) simulates the structure and functional aspects of
human brain neural network. The weight of neuron connection can
be changed to be a suitable value after learning knowledge from
training data set. To predict the correlation of expression strength
and regulatory sequences [46], a precise ANN model was built in
our lab to predict the strength of Trc promoter& RBS elements with
a high regression correlation coefﬁcient of 0.98 for both model
training and test. Furthermore, the quantitative design sequences
with desired strength were also successfully applied to improve the
expression of a small peptide BmK1 and ﬁne-tune a key enzyme
gene dxs for pathway engineering of terpenoids biosynthesis in
E. coli. This research demonstrate that the methodology based on
machine learning models can de novo and quantitatively design
regulatory elements with desired strengths, which are of great
importance for synthetic biology applications.
As to natural protein coding sequences, it is crucial for metabolic
engineering a target in biosynthetic biology. For several decades,
biosynthetic scientist assembled the native coding sequences to
create the genetic pathway in a heterologous host. But the titer is
always remarkable low. Codon optimization, modifying the coding
sequence of an individual gene without altering the amino acid
sequence, are widely used in heterologous cells in order to
increasing the yield of protein expression under the control of a
given promoter. It has been known that the choice of synonymous
codons in many species is strongly biased and that a correlationexists between high expression and the use of selective codons in a
given organism. Additionally, mutagenesis was operated by
computational chemistry to model binding sites and active sites
with key residues mutated to confer altered enzymatic activity or
high-level expression. However, the 3D structure is not always easy
to obtain leading to the modiﬁcation of proteins are not always
highly effective. And the mutations were operated basing on semi-
empiricism such as terminal truncation, domains replacement.
Synthetic biologists are still working on designing the most efﬁ-
cient enzyme for a speciﬁcity engineering pathway.
3. Parts assembly and pathway engineering in chassis cells
For the purpose of synthesizing a desirable natural product in
chassis cells, the biosynthetic pathway need to be totally designed,
assembled and engineered. According to the synthesis pathway and
the character of module parts, many different microbes, Escherichia
coli, Saccharomyces cerevisiae, and Myxococcus xanthus has been
used as the chassis cells for production of many natural products
successfully. It is a great advance that the interchangeable biolog-
ical parts are used and assembled quickly in synthetic biology,
which had better to be standardized previously. Biological parts, or
devices are not independent objects, they typically function within
a cellular environment. When these artiﬁcial parts were introduced
into the cells, drastic inﬂuence on cells' physiology would be
appeared. It this section, we will describe the parts assembly and
the pathway engineering in chassis cells.
3.1. BioParts assembly
Synthetic biologist seeks to engineer new function in biological
system for variety of applications. A key limitation in synthetic
biology is the time taken to assemble genes or other DNA parts into
new devices, pathways and systems, or to alter these assemblies for
recycling purpose. Considerable efforts have been invested into
developing new tools for DNA assembly over past four decades. At
present, popular DNA assembly methods are mainly based on four
disciplines: restriction endonuclease based assembly, homology-
dependent assembly, site-speciﬁc recombination strategies, and
homing endonucleases based assembly technology. (summarized
in Table 2, Fig. 1).
One of existing assembly methods rely on restriction enzymes
digestion followed by ligation to join DNA segments together.
Although this approach works well for the insertion of a single DNA
sequence into a vector, it is often hard to ﬁnd enough distinct re-
striction sites for the cloning of multiple DNA fragments. BioBrick
and BglBrick, are two standardized techniques in the process of
DNA assembly by using standard restriction sites [47e49].Biological
parts were ﬂanked by four restriction sites and the assembly
products of the ﬁrst round can subsequently be used in the next
round, thus permitting the assembly of multiple parts. This
approach has proven to be very effective while time-consuming as
well as forbidden sites limitation especially for multiply sequences
assembly. Golden gate assembly is an advanced approach, which
uses the activity of type II restriction enzymes (eg., Bsa I and Bsm
BI) to cut outside of their recognition sequences to expose designer
overhangs. Multiply DNA sequences assembly can be enabled in
one-pot reaction with designed direction seamlessly [50,51].
Another class is homology-dependent assembly in vitro or
in vivo that work by joining DNA fragments with homologous se-
quences, usually between 20 bp and 40 bp at the end. The long
sequence homology ensures high efﬁciency and speciﬁcity of DNA
assembly, meaning that most long-overlap-based methods can
easily assemble ﬁve or more DNA parts together in one step. These
methods are particularly popular for manipulating larger DNA
Table 2
DNA assembly strategies and standards for synthetic biology.
Classes Standards PCR required Forbidden restriction sites Multipart assembly Scar References
Restriction and ligation BioBrick No 4 No Yes Knight [47];
Shetty et al. [48]
BglBrick No 4 No Yes Anderson et al. [49]
Golden gate assembly No 1 Yes No Engler et al. [50]
Engler et al. [51]
Homology-dependent assembly In-fusion No No Yes No Berrow et al. [53]
SLIC No No Yes No Li et al. [52]
Gibson isothermal assembly No No Yes No Gibson et al. [54]
CPEC Yes No Yes No Horton et al. [55]
LCR Yes No Yes No Kok et al. [56]
Site-speciﬁc recombination SSRTA (4BT1 integrase) No No Yes No Zhang et al. [57]
SIAR (4C31 integrase) No No Yes No Colloms et al. [58]
Homing endonucleases iBrick No No No Yes Liu et al. [59]
C-Brick No No No Yes Li et al. [60]
CPEC, circular polymerase extension cloning; LCR, ligase cycling reaction; SIAR, serine integrase recombinational assembly; SLIC, sequence and ligase independent cloning;
SSRTA, site-speciﬁc recombination-based tandem assembly.
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restriction sites from within parts. These include SLIC (sequence
and ligase independent cloning) [52],In-Fusion technologies
[53],the Gibson isothermal assembly method [54],CPEC (circular
polymerase extension cloning) [55],LCR (ligase cycling reaction)
[56]and so on. The mechanism of these methods varies greatly. For
example, CPEC is based on overlap extension PCR and is essentially
a high-ﬁdelity PCR ampliﬁcation, infusion technology is worked in
the present of recombinase in vitro.
Site-speciﬁc recombination omits any need for restriction en-
donucleases and instead uses phage integrases, which are site-
speciﬁc recombinases that recognize versions of attachment (att)
sequence motifs and catalyse DNA rearrangement between them.
Integrases are utilized in the popular commercial Gateway cloning
method, which uses l integrase in vitro to catalyse directional
cloning of DNA parts that are ﬂanked by orthogonal versions of the
attB and attP sites recognized by the integrase. Similar non-
commercial systems have also been developed that use alterna-
tive phage integrases. Zhang et al. [57]efﬁciently, accurately, and
tandemly assembles epothilone biosynthetic gene cluster by
Streptomyces phage 4BT1 integrase. Colloms et al. [58]assembled
functional carotenoid biosynthetic pathways containing three, four
or ﬁve genes pathways in E. coli by bacteriphage 4C31 integrase.
Homing endonucleases, which recognize long DNA sequences is
newly developed DNA assembly technology. A new standard iBrick,
which uses two homing endonucleases of I-SceI and PI-PspI was
introduced by Liu et al. [59] Both enzymes recognize long DNA
sequences (>18 bps), which in extremely rare in natural DNA se-
quences, there is usually no need for modiﬁcation of the DNA se-
quences regardless of their length. Using this standard, the
carotenoid biosynthetic cluster was successfully assembled and the
actinorhodin biosynthetic cluster was easily cloned and heterolo-
gously expressed. Another DNA assembly stand, namely C-Brick
stand, was developed recently with a crRNA-guided endonuclease,
a class 2 type V CRISPR-Cas systems protein FnCpf1 [60]. It mainly
cleaves target DNA sequences with the “18e23” cleavage pattern
downstream of the protospacer adjacent motif (PAM) site. But, for
some target sequences, cleavage nearby the two sites could also be
detected, which cause the lower assembly efﬁciency and incorrect
assembly. Therefore, it is very important to ﬁnd new Cpf1s or
perform protein engineering of the present Cpf1s to enhance the
accuracy of Cpf1 digestion in future.
3.2. Pathway engineering in chassis cells
A module is a compartmentalized set of parts/devices withinterconnected functions that performs complex tasks. Generally
speaking, in a cell, modules are speciﬁc pathway, such as a meta-
bolic pathway or a signal transduction pathway. However, the
optimization and balancing of multigene pathways are a challenge
when introduced into a heterologous cell. Multiple rounds of con-
struction, debugging, and ﬁne-tuning are needed for chemical
improvement, which is inefﬁcient and time-cousming. Therefore,
module pathway engineering has emerged as a promising strategy
to solve this problem, which artiﬁcially divides metabolic pathway
in to various modules, constructs artiﬁcially controlled modules
with various expression level, and assemblies of multiple modules
simultaneously for generating strain library.
Biologist always divides a metabolic pathway into at least two
modules-upstream module and downstream module, and the
different function module were assembled into separated vectors.
The former produce theprimarymetabolites,which is themainly the
precursor of target chemical and act as the reactant for the down-
stream action. And the upstream module might present in the cho-
sen chassis. Typically the ﬂux toward the product is naturally lowbut
through the useof classical strain improvementor the useof directed
genetic modiﬁcations, it is possible to increase the ﬂux toward the
product and it is the routine strategy for high yield. Many other
strategies have also been employed for modules engineering
including: (1) Over-expression of the limited step enzymes; (2)
Deletion or down regulation of bypass genes; (3) Promoters engi-
neering; (4) Interchange of natural proteins from range of livings; (5)
Modiﬁcation of rate-limiting enzymes; (6) transporter engineering.
In this section, I will introduce several cases for natural product
pathway engineeringwith the strategies abovementioned (Table 3).
3.2.1. Isoprene
The IspS enzymes have very high Km values. Because of the low
afﬁnity of IspS for DMAPP, the protein fusions of IPP isomerase (IDI)
and IspS were constructed based on the hypothesis that these fu-
sions might improve isoprene production by providing a high local
concentration of DMAPP to IspS. Overexpression of the IDI and
P. alba IspS enzyme fusions, especially the IDI-IspS fusion, has
increased isoprene production in a cyanobacterium [40]. In vitro
assays using equimolar amounts of puriﬁed enzymes conﬁrmed
that the IDI-P. alba IspS fusion effectively increased the rate of IPP
conversion to isoprene. Presumably, the DMAPP produced by IDI
was channeled toward the active site of IspS in the fusion without
being released into the surrounding environment, thereby
increasing the rate of isoprene synthesis. This work demonstrates
that the use of synthetic fusion proteins can successfully improve
product yields in cyanobacteria.
Table 3
Heterologous biosynthesis of important natural products.
Target products Hosts Engineering strategies Yield References
Isoprene Synechococcus elongatus Codon optimization; and protein fusion (IDI-IspS) 1.2 g L1 Gao et al. [40]
Amorphadiene E. coli Exploiting exogenous MEP pathway genes dxs, ispD, ispF, and idi from four
bacteria Erwinia taxi, Streptomyces, avermitilis, Saccharopolyspora erythraea, and
Bacillus subtilis to improve isoprenoid production.
232 mg L1 Wang et al. [61]
E. coli Transporter engineering (Overexpression of native efﬂux pumps AcrAB-TolC,
MdtEF-TolC; Overexpression of exogenous pumps mexAB-OprM; and
Modulating the copy number of pump).
404 mg L1 Wang et al. [68]
ent-Kaurene E. coli Transporter engineering. 32 mg L1 Wang et al. [68]
Rebaudioside A E. coli Modules standardization; Codon optimization; N terminus truncation and
substitation; and KAH replacement.
10 mg L1 Wang et al. [64]
Compound K S. cerevisiae EST database mining; Enzymatic UGT characterization; and Prompter
replacement.
1.4 mg L1 Yan et al. [39]
Ginsenoside F1 S. cerevisiae UGTPgs characterization; Structural modeling; Protein chimeric. 42 mg L1 Wei et al. [65]
Ginsenoside Rh1 S. cerevisiae Same as ginsenosides F1. 92 mg L1 Wei et al. [65]
Ginsenoside Rh2 S. cerevisiae Yeast chromosomes integration; Cell factories establishment. 0.17 g L1 Wang et al. [66]
Ginsenoside Rg3 S. cerevisiae Same as ginsenosides Rh2. 0.5 g L1 Wang et al. [66]
6-dEB E. coli Transporter engineering; and regulatory factor modulating. 59 mg L1 Yang et al. [69]
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Amorphadiene is the important intermediate of artemisinin.
The precursor DMAPP/IPP is originated fromMEP pathway. And the
same pathway is also present in many living organisms. For pro-
ducing high-level of DMAPP/IPP in E. coli, Wang et al. [61] screened
the elementary library to get the rate-limiting genes dxs, ispD, ispF,
idi from a wide range of microorganisms and assembled into the
native MEP pathway. The results show that dxs2 derived from
Streptomyces avermitilis, ispF from E. coli, ispD from S. erythraea, and
idi from Bacillus subtilis highly improve the metabolic ﬂux of MEP
pathway. Finally, this interchange strategy enhanced the yield of
amorphadiene to 15.5 efold in E. coli.
3.2.3. Rebaudioside A
Rebaudioside A (RA) is an intense natural diterpenoid sweet-
eners isolated from Stevia rebaudiana. The biosynthetic pathway of
RA in Stevia plants has been largely characterized and it involved
nine enzyme-catalytic reactions from isopentenyl diphosphate/
dimethylallyl diphosphate [62,63]. The pathway then was divided
into three metabolic modules: terpene synthetic module, cyto-
chrome P450 module, and glycosylation module for de novo
biosynthesis of RA in E. coli. [64] Each module has been test and
optimized before transferred into the host. The ﬁrst module has
been established in the preciously work and the maximum yield of
ent-kaurene, the precursor of RA, was 194 mg/L (in shake ﬂask) and
1.8 g/L (in a 5-L bioreactor). Of the second module building, two
P450 enzymes ent-kaurene oxidase (KO) and KAH are responsible
for the sequential C19 oxidation and C13 hydroxylation of ent-
kaurene, respectively. The KO was incorporated along with an
electron transfer partner CPR, and the KAH was replaced by
CYP714A2 from A. thaliana together with N terminus engineering
resulted in 17atr29CYP714A2 to produced 15.47 mg/L of steviol,
which was enhanced to 25.6-fold compared with KAHn2. After-
wards, the UGT module UGT85C2/UGT91D2w/UGT74G1/UGT76G1
was further assembled and incorporated into the highest steviol
producer with 17atr29CYP714A2 to achieve the complete biosyn-
thesis of GA in E. coli and the yield reached 10.0 mg/L.
3.2.4. Compound K
Compound K (CK) is the major ginsenoside-type metabolite
detected in vivo after oral administration of ginseng in mammals,
which has not been detected from Panax plants. It is testiﬁed to
possess bioactivities of anti-inﬂammation, hepatoprotection, anti-
diabetes and anti-cancer. The identiﬁcation of the novel UDP-
glycosyltransferase, UGTPg1, which could selectively glycosylatethe C-20(S)-OH of PPD is the key point to build a yeast cell factory to
produce CK from simple sugars. After co-expression of UGTPg1
with the PPD biosynthetic pathway in the chassis yeast, CK could be
produced from cheap monosaccharide via microbial fermentation
[39].A novel compound, 20S-O-b-(D-glucosyl)-dammarenediol II
was discovered and identiﬁed in the CK producing yeast, which is
readily converted to CK by a P. ginseng cytochrome P450 in vitro.
Thus, two parallel pathways for CK production in the engineering
yeast cell as well as in Panax plant are supposed. The ‘one-pot’
biosynthesis of CK in yeast provides not only a potential low-cost
CK manufacturing method for its clinical applications, but also
the scientiﬁc bases for understanding the biosynthetic pathways of
ginsenosides in Panax plants.
3.2.5. Rare ginsenosides
Rh2, Rg3, Rh1 and F1 are all rare ginsenosides, and their con-
tents in ginseng are extremely low. For example, Rh2 is almost
undetectable in the total ginsenosides of Panax plants (P. ginseng,
P. quinguefolium, and P. notoginseng), and the Rg3 is only detected in
the total ginsenosides of P. ginseng; its content in the dry ginseng is
about 0.0003%. To build yeast cell factories to produce rare ginse-
nosides, a yeast chassis to produce PPD or PPT with high yield was
built by enhancing the MVA pathway of S. cerevisiae as well as
integrating the genes related to PPD or PPT biosynthetic pathway
(gene encoding PgDDS, CYP716A47, PgCPR1and CYP716A53v2) into
its chromosome [65,66]. And then the characterized UGTPgs were
introduced into the PPD or PPT producing chassis to obtain the
yeast cell factory producing different rare ginsenosides.
3.2.6. Transporter engineering
The tolerance of chassis cells to heterogenous compounds are
key point for high level production. Thus, expelling heterologous
compounds out of hosts by transporters is a potential strategy to
enhance product titers in microbial cell factories. Microorganisms
have evolved membrane transporters that recognize and export
toxic compounds from the cell and sustain their survival by
exporting awide range of substrates, antibiotics, chemotherapeutic
agents, and solvents [67].The general engineering strategies for the
product transportation modules are: (1) over-expression of efﬂux
pump genes; (2) combinatorial expression of efﬂux pump compo-
nents; (3) introduction of exogenous transportation modules and
design of artiﬁcial transportation system.
The pleiotropic resistant pumps, such as AcrAB-TolC from E. coli
and MexAB-OprM pump from Pseudomonas aeruginosa has been
veriﬁed the function that expel a wide range of relevant antibiotics
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pene) and kaurene (diterpene) production, Wang et al. [68]over-
expressed, systemtically assembled and modulated these efﬂux
pumps in E. coli. The overexpression of AcrB and TolC components
can effectively enhance the speciﬁc yield of amorphadiene and
kaurene, e.g., 31 and 37% improvement, respectively. The heterol-
ogous MexB component can enhance kaurene production with 70%
improvement which is more effective than TolC and AcrB. The re-
sults suggest that the three components of tripartite efﬂux pumps
play varied effect to enhance isoprenoid production. Considering
the highly organized structure of efﬂux pumps and importance of
components interaction, various component combinations were
constructed and the copy number of key components AcrB and TolC
was ﬁnely modulated as well. The results exhibit that the combi-
nation TolC and TolC and AcrB improved the speciﬁc yield of
amorphadiene with 118%, and AcrA and TolC and AcrB improved
that of kaurene with 104%.
Another example is that Yang et al. [69] modulated tripartite
multidrug efﬂux pumps MacABTolC, AcrAB-TolC, MdtEF-TolC, and
MexAB-OprM for increasing heterologous polyketide 6-
deoxyerythronolide B production. Compared with the control,
overexpression of a single component of efﬂux pumps (except
oprM) repressed 6dEB production, but modulation of two compo-
nents MacA and MacB, or the complete pumps MacAB-TolC and
MdtEF-TolC signiﬁcantly improved 6dEB titer by 100, 118, and 98%,
respectively. In addition, to avoid the challenging ﬁne-tuning
components of pumps, the transcriptional regulators of efﬂux
pumps were modulated to improve the 6dEB production. Over-
expression of RpoH (activator of MdtEF-TolC) and EvgA (activator of
EmrKY-TolC and AcrAD-TolC) strongly increased 6dEB titer by 152
and 142%, respectively. These two cases strongly suggested that
transporter engineering is a potentially effective strategy to
enhance the yield of natural products in a heterologous biological
system.
4. Computer-aided guidance for systematic optimization
The functional behavior of a module in a cell depends not only
on its component devices and their connectivity, but also on the
cellular context in which the module operates. Because synthetic
modules and endogenous cellular processes condition each other's
behavior, any ﬂuctuations in the host cell processes are relayed to
the module and affect its output and vice versa. This presents a
problem for engineering predictable, reliable biological systems.
One approach to solving this problem is predict the process utilized
computer-acidmathematicmodel and take into account amodule's
connection to the host's cellular context. Although simpliﬁcation,
speciﬁcation, and standardization make engineering easier, it may
not be advantageous to hide all the information about the host cell.
Using the knowledge-based empirical approaches, some targets
of the MEP pathway (e.g. dxs, idi, and ispDF gene) were straight-
forwardly engineering for enhancing production of isoprenoids in
E. coli. [70] A novel approach: ﬂux distribution comparison analysis
(FDCA) was developed for discovery of genomic scale metabolic
targets in E. coli. 51 knockout, down-, and up-regulated targets
were predicted and experimentally tested to enhance lycopene
production. Five signiﬁcant targets gdh A, eut D, tpi A, omp E, and
ompN were combined the lycopene titer improved by 174% in
shake-ﬂask. For further better understand the imbalance of mod-
ules in heterolugous expression system, we will gave the following
example for 6dEB production by antisense RNAs.
6-deoxyerythronolide B (6dEB) is a key intermediate of eryth-
romycin. Heterologous biosynthesis of 6dEB has been successful in
E. coli, but the conversion is still a very low molar yield range from
0.7 to 2.1%. On the contrary is that 6dEB derived from propionatecould reach up to 11.2% in E. coli, which was ﬁrst evaluated utilizing
the maximum theoretical molar yield (MTMY) by Meng et al. [71]
This extremely gap is often caused to a large extent by the imbal-
ance of heterologous biosynthetic pathway and endogenous
metabolic network.
To demonstrate the metabolic module interactions for under-
standing their imbalance, a genome-scale metabolic model
(GSMM) was constructed based on iAF1260, and another two ﬂux
distribution analysis methods, FDCA and LMOMA were used to
calculation the MTMYof 6dEB in E. coli [72]. Metabolic pathways of
the cell that interact with 6dEB biosynthesis module were totally
divided into 8 major functional modules, including (i) propionate
metabolism and 6dEB biosynthesis module; (ii) TCA cycle module;
(iii) glycolysis module; (iv) PP pathway module; (v) nucleotide
metabolism module; (vi) pyruvate metabolism module; (vii) cell
membrane constituent biosynthesismodule; and (viii) amino acid
metabolism module. The mathematic model, which simulate the
optimal growth of E. coli and 6dEB production characterize an
“ideal situation” (maximize product formation rate).
In comparison with the “actual situation”-transcriptome anal-
ysis of 6dEB production strain by microarray assay, the signiﬁcant
discrepant genes of these two situation mainly involved in the
pentose phosphate pathway module and nucleotide metabolism
module. All 25 predicted targets at these two modules were tested
for improving the 6dEB production in E. coli via synthetic antisense
RNAs. Down-regulation of 18 target genes leads to more than 20%
increase in 6dEB yield. Combinatorial repression of targets with
greater than 60% increase in 6dEB titer, e.g., anti-guaB/anti-zwf led
to a 296.2% increase in 6dEB production (210.4 mg/L in ﬂask). This
study strongly demonstrated that the synthetic 6dEB module not
only interfaced with connecting pentose phosphate pathway
module, but also with nucleotide metabolism module in cellular.
5. Perspective
Synthetic biology is an emerging ﬁled with the development
with DNA sequencing technology, DNA recombinant technology,
computational biology, and biological engineering. It distinguishes
itself from other disciplines in both its approach and its choice of
object. Synthetic biology should be considered a hybrid discipline,
combining both engineering and science to achieve its goal of en-
gineering synthetic organisms. The aim of this discipline for pro-
ducing a genetic product in a host cell may be not an issue in term
of biological parts characterization and DNA assembly, but the
modules interfacing in the future.
Biological systems are dynamic, ﬁne regulated, nonlinear com-
plex systems [73]. It possessed a far greater degree of integration of
their parts than that of non-living systems. However, the behavior
of most synthetic modules has been studied in isolated cells. The
function of a synthetic module may fundamentally affect host cell
processes, thus altering the cellular context. This situation is further
complicated and reprogramming the cell is required, which in-
volves the creation of synthetic biological components by adding,
removing, or changing genes or proteins [74]. In the multiply
rounds of design, construction, and testing of new cellular com-
ponents, researchers need to develop feasible and precisely pre-
dicted tools and effective methods for module construction. As a
result, design of synthetic biological systems has become an iter-
ative process of screening, modeling, construction, and testing that
continues until a system achieves the desired behavior. Rational
redesign based onmathematical models improves system behavior
in such situations. These retooled systems are once again tested
experimentally and the process is repeated as needed. Many syn-
thetic biological systems have been engineered successfully in this
fashion because the methodology is highly tolerant to uncertainty.
J. Li et al. / Synthetic and Systems Biotechnology 1 (2016) 221e229228Synthetic biology will beneﬁt from further such development and
the creation of new methods that manage uncertainty and
complexity.
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